Saggy skin with Mounjaro: what the evidence actually shows

What the trial data tells us about the scale of weight loss, and why skin matters

The SURMOUNT-1 study, published in the New England Journal of Medicine, found that adults taking tirzepatide at the highest dose lost around 20–21% of their body weight on average over 72 weeks. For someone starting at 100 kg, that is roughly 20 kg gone in under two years. Losses of that magnitude sit well above the threshold at which dermatologists observe meaningful changes in skin elasticity.

Skin stretches to accommodate excess weight by laying down additional collagen fibres and expanding fat deposits under the dermis. When that weight comes off, the underlying support structure shrinks faster than the outer skin can contract. The result (loose, sagging tissue) is most common around the abdomen, upper arms, thighs and chest. None of this is unique to Mounjaro; the same physics applies after bariatric surgery, long-term dietary restriction, or any intervention that produces large sustained losses.

What trial data cannot tell us is exactly who will be affected. SURMOUNT-1 did not measure or report skin laxity as an outcome. The NHS medicines page for tirzepatide does not list saggy skin as a side effect because it is not a pharmacological action of the drug itself, it is a mechanical consequence of the weight change the drug helps produce. If you are wondering whether you will get loose skin with Mounjaro, the honest answer depends on individual factors that no trial has yet captured in a systematic way.

The factors that determine how your skin responds to significant weight loss

Age is probably the single biggest predictor. Collagen and elastin production decline steadily from the mid-twenties onward, so a 50-year-old losing 25 kg is more likely to notice loose skin than a 28-year-old losing the same amount. Skin that has been stretched for longer (through years of carrying excess weight) also tends to have less recoil capacity remaining.

Genetics matter too, in ways that are difficult to quantify in advance. Some people have skin that contracts remarkably well after large losses; others notice laxity after losses of even 10–15%. Sun exposure history, smoking, and prior rapid weight-loss cycles can all reduce the skin's remaining elastic capacity before Mounjaro is ever started.

The pace of loss is the factor most often cited as modifiable. Rapid weight loss leaves less time for the slower biological process of skin remodelling. Mounjaro's titration schedule (starting at 2.5 mg and stepping up gradually) tends to produce weight loss that accelerates as the dose increases, rather than a steep drop from week one. Whether that gradient is shallow enough to make a meaningful difference to skin outcomes has not been directly studied, and it would be misleading to present the titration schedule as a skin-laxity intervention. What it does do is allow the body to adjust progressively, which most clinicians consider preferable on multiple fronts. For a fuller look at what's known about skin changes specifically, the Mounjaro and saggy skin guide covers the clinical picture in more detail.

What you can do, and what the evidence supports

Three lifestyle factors have reasonable evidence behind them for supporting skin during weight loss: resistance training, protein intake, and hydration. Resistance exercise helps preserve (and in some cases build) lean muscle mass beneath the skin, which provides structural support and reduces the sunken appearance that can accompany fat loss alone. The NHS's healthy weight guidance recommends strength activity alongside any weight-management programme, and this matters more, not less, when losses are substantial.

Protein is the raw material for collagen synthesis. During calorie restriction on Mounjaro, appetite falls significantly, which means total food intake drops. People sometimes find their protein intake falls with it. Keeping protein adequate (most adults aim for 1.2–1.6 g per kg of body weight when in a caloric deficit) is something worth discussing with your prescriber or a registered dietitian. Hydration keeps skin pliant and supports general tissue health, though it will not reverse established laxity.

Topical products, collagen supplements, and skin-tightening treatments are widely marketed but the evidence base is thinner. None should be dismissed out of hand, but none replace the fundamentals. If you are researching practical strategies before or during treatment, the guide on avoiding saggy skin on Mounjaro pulls together the most useful options. For context on what Mounjaro treatment involves more broadly, the Mounjaro overview is a good starting point.

Having an honest conversation with your prescriber

Skin laxity is worth raising before you start treatment, particularly if you are planning to lose a substantial amount of weight or have had previous rapid weight-loss experiences. A prescriber cannot predict your individual outcome, but they can help you set realistic expectations, flag if any underlying conditions might affect tissue healing, and refer you to relevant support if needed.

The concern about loose skin is also sometimes used (unhelpfully) as a reason to avoid treatment altogether. For people living with obesity and its associated health risks, the cardiovascular, metabolic and joint benefits of significant weight loss almost always outweigh the aesthetic trade-offs. That calculation is personal and clinical; it is exactly the kind of thing a prescriber is there to work through with you. If you are still forming a view on whether tirzepatide is right for you, reading about how tirzepatide works can help frame the decision. There is also a broader look at weight-loss treatment options if you want to compare approaches before going further. On cost, the context around Mounjaro's UK pricing is worth understanding, since Eli Lilly raised list prices significantly from September 2025. When you are ready to speak to a prescriber, checking your eligibility is a straightforward first step with no obligation.